CuraRN

NSG210 Durham Ch. 18: Well Women’s Health

Source: Durham & Chapman, Maternal-Newborn Nursing 4e, Chapter 18, pp. 595-613 (textbooks/DURHAM_OB_CH18.pdf, also in textbooks/exam03/). Week 10 reading; on Exam 3. Lecture slides: raw/nsg210_wk10_OBLecture4.md (Menopause section). Gynecologic disorders are in nsg210-durham-ch19-alterations-womens-health; osteoporosis in med-surg is in nsg210-hinkle-ch36-musculoskeletal-disorders.

Learning Outcomes

  1. Identify factors that put women at risk for adverse health conditions.
  2. Discuss preventive screenings across the life span.
  3. Describe how diet, exercise and smoking affect women’s health.
  4. Discuss the effects of obesity.
  5. Discuss physical and emotional changes of perimenopause and menopause.
  6. Discuss screening for intimate partner violence.
  7. Describe the health care needs of LGBTQ women and their barriers to care.
  8. Develop a health promotion plan for an older adult based on normal aging.

Nursing diagnoses: risk for adverse health conditions (knowledge deficit about health promotion); knowledge deficit about menopause; risk for disturbed sleep (night sweats); risk for falls (impaired balance).

I. Health Promotion and Risk Reduction

Critical Component, warning signs in women:

Risk reduction actions:

Critical Component, HPV: the most common sexually transmitted virus in the US; main cause of cervical cancer and genital warts; also vulvar, vaginal, penile, anal and oropharyngeal cancers.

HPV vaccine (Gardasil, Gardasil 9): prevents those cancers and genital warts; IM; injection site reaction. Started before age 15: 2 doses (second at 6 to 12 months). Started at 15 or older: 3 doses (at 0, 1 to 2, and 6 months). Teach: complete the series; still need routine cervical screening; does NOT prevent other STIs.

Critical Component, obesity: Class 1 BMI 30 to 35; Class 2 BMI 35 to 40; Class 3 BMI over 40. Risks: hypertension, coronary heart disease, type 2 diabetes, stroke, cholecystitis, sleep apnea, cancers (endometrial, breast, colon, kidney, gallbladder, liver), osteoarthritis of knee, hip and back, abnormal menses and infertility, high-risk pregnancy, miscarriage, macrosomia.

II. Routine Screening (Table 18-2)

Screening 19-39 40-49 50-64 65+
Blood pressure Every 1-2 years Every 1-2 years Every 1-2 years Every 1-2 years
Cholesterol Start at 20; regularly if at risk Regularly if at risk Regularly if at risk Regularly if at risk
DXA bone density     Based on history and osteoporosis risk Based on history and risk
Type 2 diabetes Yearly if overweight with risk Yearly if overweight; yearly over 45 Yearly Yearly
Mammogram   Discuss with provider Discuss with provider Discuss with provider
Cervical cancer Pap every 3 years (19-29); Pap plus HPV every 5 years from 30 Pap plus HPV every 5 years Pap plus HPV every 5 years Based on history
Chlamydia Yearly to age 24 if sexually active; 25-39 if new or multiple partners If new or multiple partners If new or multiple partners If new or multiple partners
Colonoscopy     Every 10 years from 50 Every 10 years to 75
Eye exam If problems Baseline at 40, then every 2-4 years Every 2-4 years Every 1-2 years
Hearing Every 10 years Every 10 years Every 3 years Every 3 years
Skin Monthly mole self-exam; provider every 3 years from 20 Monthly self; yearly provider Monthly self; yearly provider Monthly self; yearly provider
Dental and oral cancer Yearly Yearly Yearly Yearly

All pregnant women are tested for various STIs.

Breast cancer screening:

Critical Component, screening mammogram: low-dose x-ray with the breast compressed between plates (feels squeezed or pinched); compared with prior films for lumps, abscesses, calcifications; abnormal results need diagnostic mammogram, ultrasound, MRI or biopsy. Tell the facility about implants. NO deodorant, perfume, lotion or powder under the arms or on the breasts that day (they cast shadows).

Cervical cancer screening (American Cancer Society): stop after 65 if no precancer in the previous 10 years; stop after total hysterectomy unless done for cervical precancer or cancer; HPV-vaccinated women still follow screening guidelines.

III. Intimate Partner Violence (IPV)

Clinical Judgment, trauma-informed care:

IV. Reproductive Changes

Puberty:

Menopause:

Signs and symptoms:

Critical Component, menopause and sexual well-being: declining estrogen thins vaginal tissue and reduces secretions, causing dryness and dyspareunia; sleep loss, hot flashes and mood changes also affect sexual well-being.

Treatment approaches:

Specific discomforts:

Nursing: patient education. Menopause is a natural phase; review her symptoms and relief methods; discuss sexual well-being; teach lifestyle, medication and alternative options.

V. Osteoporosis

Risk reduction:

ACOG recommends drug therapy for: a fragility (low-impact) fracture; T score -2.5 or lower; or risk factors with T score below -1.5.

Bisphosphonates (inhibit bone resorption; side effects musculoskeletal aches, GI irritation, ESOPHAGEAL ULCERATION):

Patient Education, alendronate:

Other drugs:

Nursing (education): risk factors; FALL PREVENTION (remove throw rugs, clear floors, light stairways, grab bars by shower, tub and toilet, yearly eye exams, limit alcohol, wear shoes inside and out); purpose of DXA; calcium and vitamin D foods; activity; medications; smoking and alcohol.

VI. Specific Populations

A. Adolescents (ages 12 to 19)

B. Older adult women

Table 18-4, age-related changes and health promotion:

Change Effect Health promotion
Less muscle mass Less strength Strength training, healthy diet
Less body water, renal changes Dehydration risk At least 8 glasses of fluid spread through the day
Less smell and taste Poor appetite Healthy gums and teeth; colorful food
Slower metabolism, more fat, less muscle   Fewer calories, more activity, strength training
Fewer T cells, less lung elasticity and airway clearance Infection and pneumonia risk Diet, hand washing, activity, yearly flu vaccine, pneumococcal vaccine (PPSV23)
DNA damage with less repair Cancer risk Cancer screening
High-frequency hearing loss Trouble recognizing speech Hearing evaluation and treatment
Less peripheral vision and depth perception, cataracts Poor eyesight Eye exams, sunglasses when driving
Slower intestinal motility Constipation Daily exercise, fluids, fruit, vegetables, whole grains, probiotics
Less bladder elasticity, prolapse, cystocele Frequency, incontinence, cystitis Ideal weight, bladder training, double voiding, timed voiding, Kegels
Weak legs, vertigo, vision changes, dehydration, hypotension, confusion, foot problems, arthritis Falls Fall risk evaluation; lighting, no loose rugs, grab bars; medication adjustment; flat nonskid shoes; yearly vision checks
Osteoporosis Fractures Calcium foods, vitamin D 600 to 800 units, weight-bearing exercise, stop smoking
Thicker heart walls and valves, larger heart CVD, hypertension, atrial fibrillation Heart-healthy diet, exercise, no smoking, treat diabetes, hypertension, lipids
Less baroreceptor sensitivity Orthostatic hypotension Rise SLOWLY
Atherosclerosis, atrial fibrillation Stroke Low saturated and trans fat, cholesterol and sodium; treat risk conditions; activity
Less liver mass and blood flow, lower GFR Adverse drug reactions Tell providers and pharmacist all drugs including OTC and herbal; follow directions; report changes
Prefrontal cortex and hippocampus changes Changes in learning, memory, planning Control BP and diabetes; vitamin B12 2.4 mcg; exercise; diet; mental stimulation; social connection

Other areas:

Estradiol vaginal cream (Estrace): atrophic vaginitis of menopause; relieves vaginal dryness and soreness, vulvar itching and redness, urinary urgency and dysuria. 0.5 to 1 g vaginally daily for 2 weeks, then twice weekly. Side effects: breast pain or enlargement, genital itching, headache, nausea, stinging, thick white mild-odor discharge. Use at BEDTIME for better absorption; NOT right before intercourse (limits partner exposure); ask about use with latex condoms, diaphragms and caps.

Driving: changes in vision and reflexes; giving up driving threatens independence. Conditions that interfere: dementia, vision and hearing changes, stroke, Parkinson disease, arthritis, diabetes, some drugs. Promote yearly eye exams, no drinking and driving, avoid night and bad-weather driving, limit distractions (radio, talking, phones), avoid sedating drugs, sunglasses.

Critical Component, signs driving is no longer safe: trouble seeing or following signals, signs and markings; stopping at green lights or where there is no stop sign; confusion at signals; running stop signs or red lights; getting lost in familiar places; dents and scrapes on the car, fence, mailbox or garage; slower responses; trouble moving the foot from gas to brake.

Nursing: discuss age-related changes; individualized teaching plan and health promotion.

C. Lesbian health (LGBTQ)

High-Yield Numbers

Priority Nursing Actions and Red Flags

Medications

Drug Class Dose (per chapter) Key points
HPV vaccine (Gardasil, Gardasil 9) Vaccine IM; 2 or 3 doses by age Complete series; still screen; no protection from other STIs
Estrogen (oral, transdermal, vaginal) Hormone Lowest effective dose Alone only if no uterus; contraindications above
Estrogen plus progesterone Hormone   If uterus present; protects endometrium
Fluoxetine, gabapentin, clonidine Off-label for hot flashes Low dose  
Alendronate (Fosamax) Bisphosphonate Prevention 5 mg/day or 35 mg/wk; treatment 10 mg/day or 70 mg/wk Empty stomach, water, upright 30 minutes
Ibandronate (Boniva) Bisphosphonate 150 mg/month PO or 3 mg IV every 3 months  
Risedronate (Actonel) Bisphosphonate 5 mg/day  
Zoledronate (Reclast) Bisphosphonate 5 mg IV every 2 years (prevention) or yearly (treatment)  
Denosumab (Prolia) Monoclonal antibody 60 mg SubQ every 6 months Hypocalcemia; jaw osteonecrosis; when bisphosphonates not tolerated
Teriparatide (Forteo) Parathyroid hormone analogue 20 mcg SubQ daily High fracture risk, glucocorticoid use
Raloxifene (Evista) Selective estrogen-receptor modulator 60 mg/day VTE, leg cramps, stroke death
Conjugated estrogen plus medroxyprogesterone (Premphase) Hormone therapy 0.625 mg days 1-14; MPA 5 mg days 15-28 With uterus
Conjugated estrogen (Premarin) Hormone therapy 0.3 to 1.25 mg/day Without uterus
Estradiol vaginal cream (Estrace) Topical estrogen 0.5 to 1 g daily for 2 weeks, then twice weekly At bedtime; not just before intercourse
Calcium, vitamin D Supplements See targets